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Antibody-mediated rejection (AMR) is a principal cause of acute and chronic failure of lung
allografts. However, mechanisms mediating this oftentimes fatal complication are poorly
understood. Here, we show that Foxp3+ T cells formed aggregates in rejection-free human
lung grafts and accumulated within induced bronchus-associated lymphoid tissue (BALT) of
tolerant mouse lungs. Using a retransplantation model, we show that selective depletion of
graft-resident Foxp3+ T lymphocytes resulted in the generation of donor-specific antibodies
(DSA) and AMR, which was associated with complement deposition and destruction of
airway epithelium. AMR was dependent on graft infiltration by B and T cells. Depletion of
graft-resident Foxp3+ T lymphocytes resulted in prolonged interactions between B and
CD4+ T cells within transplanted lungs, which was dependent on CXCR5-CXCL13.
Blockade of CXCL13 as well as inhibition of the CD40 ligand and the ICOS ligand
suppressed DSA production and prevented AMR. Thus, we have shown that regulatory
Foxp3+ T cells residing within BALT of tolerant pulmonary allografts function to suppress B
cell activation, a finding that challenges the prevailing view that regulation of humoral
responses occurs peripherally. As pulmonary AMR is largely refractory to current
immunosuppression, our findings provide a platform for developing therapies that target
local immune responses.
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Introduction
Lung transplantation is the only treatment available for numer-
ous patients suffering from end-stage pulmonary failure. Com-
pared with outcomes for other organ transplants, that after lung 
transplantation remains far worse, with a median survival of 
approximately 6 years (1). Immunosuppressive strategies for lung 
transplant patients have been developed largely based on experi-
ence with transplant of other organs, such as kidneys and livers. 
However, we and others have shown that immune responses to 
lungs are substantially different from those to other transplanted 
organs, raising concern about the efficacy of treatment algorithms 
currently used in the clinics (2). Lungs provide a suitable environ-
ment for the activation of immune cells, setting pulmonary grafts 
apart from other transplantable solid organs, where the genera-
tion of immune responses depends on trafficking to draining sec-
ondary lymphoid organs (3–6). To this end, we have shown that 
both proinflammatory and regulatory immune pathways can be 
generated within the lung graft itself (6, 7).
We have previously reported that CD44hiCD62LhiCCR7+CD8+ 
central memory T cells are critical for inducing tolerance after lung 
transplantation (5). Mechanistically, we demonstrated that acute 
cellular rejection is prevented by graft-infiltrating central memory 
CD8+ T cells through IFN-γ–dependent induction of nitric oxide 
production. Interestingly, acute cellular rejection in the absence 
of CD8+ T lymphocytes was associated with reduced frequencies 
of graft-infiltrating CD4+Foxp3+ T cells early after transplantation. 
This raises the possibility that CD8+ T cell–mediated induction of 
tolerance facilitates enrichment of the pulmonary graft with Foxp3+ 
cells. We have also observed that, at later stages, bronchus-associ-
ated lymphoid tissue (BALT) is induced in accepted murine lung 
allografts and enriched in Foxp3+ T cells (7). In this study, we used 
a murine lung retransplant model to determine whether graft-res-
ident Foxp3+ T lymphocytes are critical to maintaining a tolerant 
state. Interestingly, when graft-resident Foxp3+ T cells were deplet-
ed from long-term tolerant grafts, donor-specific antibodies (DSA) 
were produced, and surprisingly, grafts underwent antibody-medi-
ated rejection (AMR), a rejection pattern distinct from the acute cel-
lular rejection previously observed when CD8+ T cells were absent 
during tolerance induction. AMR following depletion of Foxp3+ cells 
depended on graft infiltration by B and T cells and could be prevent-
ed by inhibiting pathways that mediate interactions between T fol-
licular helper (Tfh) cells and B lymphocytes. As AMR of transplant-
ed lungs is generally refractory to currently employed treatment, 
often resulting in graft failure and patient death, our findings pro-
vide a mechanistic framework for the development of new thera-
peutic strategies for this clinically vexing problem.
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observed prolonged survival compared with that in CBA cardiac 
grafts that were transplanted into naive nonimmunosuppressed 
B6 mice (Supplemental Figure 3, D–F). However, all CBA hearts 
that were transplanted into previous BALB/c lung allograft recipi-
ents were eventually rejected and displayed histological hallmarks 
of acute and chronic rejection (Supplemental Figure 3E).
Depletion of graft-resident Foxp3+ T cells triggers AMR. We have 
previously reported that long-term accepted lung grafts are not 
rejected after retransplantation into nonimmunosuppressed allo-
geneic hosts, indicating that immunoregulatory pathways are 
established in tolerant pulmonary grafts that protect them from 
immunological destruction (7). To determine whether graft-resi-
dent Foxp3+ T lymphocytes contribute to maintenance of lung tol-
erance, we took advantage of our recently described technique for 
lung retransplantation (7). To this end, we transplanted BALB/c 
lungs into B6 CD45.2 WT or B6 CD45.2 Foxp3–diphtheria toxin 
receptor (Foxp3-DTR) recipients that were treated with periopera-
tive costimulatory blockade. At least 30 days after engraftment, a 
time point when virtually all graft-resident T cells are derived from 
the recipient (Supplemental Figure 4), these lungs were retrans-
planted into nonimmunosuppressed B6 CD45.1 secondary hosts 
that were treated with diphtheria toxin (DT). Unlike DT treatment 
of primary Foxp3-DTR lung recipients, which resulted in global 
elimination of Foxp3+ cells (Supplemental Figure 5), this approach 
allowed us to selectively deplete Foxp3+ T cells that resided in the 
tolerant BALB/c lung graft at the time of retransplantation without 
targeting cells in the secondary recipient (Figure 2, A–C). Approx-
imately one-third of Foxp3+ cells that were present in control 
retransplanted grafts had originated from the primary recipient, 
while virtually all Foxp3+ cells were derived from the secondary 
host when graft-resident Foxp3+ cells were depleted at the time 
of retransplantation (Figure 2D). The majority of Foxp3+ cells in 
retransplanted tolerant lungs that were derived from the primary 
donor expressed CD4, while only a small portion expressed CD8 
(Supplemental Figure 6). Also, the proportion of Foxp3+ cells in 
retransplanted grafts that originated from the primary host was 
higher when lungs were retransplanted 30 days compared with 
72 hours after the initial transplantation (Supplemental Figure 7 
and Figure 2D). At 7 days after retransplantation, control grafts 
were ventilated, showed mild inflammation, and retained BALT 
containing B and T lymphocytes as well as PNAd+ cells, while, in 
Results
Tolerance induction after lung transplantation is associated with 
induction of Foxp3+ T cell–rich BALT and normal airway epithelium. 
Immunosuppression-mediated long-term acceptance of trans-
planted lungs is associated with the induction of BALT (Figure 
1, A and B, and Supplemental Figure 1A; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI122083DS1). Histologically normal airway architecture is not-
ed with thin epithelium (Figure 1B) resembling the appearance of 
airway epithelium in human lung grafts that have no histological 
evidence of rejection (Supplemental Figure 2A). Peripheral nod-
al addressin (PNAd), a hallmark of high endothelial venules, was 
expressed within the BALT of accepted lungs (Figure 1C). In con-
trast, PNAd was not expressed in perivascular infiltrates in lung 
grafts during acute cellular rejection (Supplemental Figure 1, B 
and C). Only minimal perivascular or peribronchiolar collagen 
was detected by Masson’s trichrome (MT) staining in the murine 
grafts (Figure 1D). The epithelium was shown to be predomi-
nantly ciliated airway epithelial cells expressing apical acetylated 
tubulin (AcT), a marker of ciliated cells, and occasional club cells 
expressing club cell secretory protein (CCSP) (Figure 1E). To fur-
ther characterize the Foxp3+ cells, we transplanted BALB/c lungs 
into C57BL/6 (B6) Foxp3-GFP recipients that were treated with 
perioperative costimulatory blockade and imaged the grafts by 
intravital 2-photon microscopy at least 30 days after engraftment. 
We visualized aggregates of Foxp3+ cells within the lung allografts, 
which displayed little motility (Figure 1F, Supplemental Video 
1). We also observed lymphoid aggregates that were enriched in 
Foxp3+ cells in human pulmonary transplant recipients that had no 
histological evidence of graft rejection at least 6 months after lung 
engraftment (Supplemental Figure 2B).
To assess whether systemic tolerance is induced after lung 
transplantation, we transplanted BALB/c hearts into B6 mice 
that had received BALB/c lungs at least 30 days prior to cardiac 
engraftment. While BALB/c hearts were acutely rejected after 
transplantation into naive nonimmunosuppressed B6 mice, they 
survived indefinitely in B6 hosts that had accepted BALB/c lung 
grafts (Supplemental Figure 3, A–C). These BALB/c hearts showed 
no evidence of chronic rejection upon histological examination 
(Supplemental Figure 3B). When we transplanted third-party CBA 
hearts into B6 mice that had previously received BALB/c lungs, we 
Figure 1. Long-term acceptance after lung transplantation is asso-
ciated with induction of Foxp3+ cell–rich BALT. (A) Gross and (B) 
histological appearance (H&E) of BALB/c lung graft (Tx) at least 30 
days after transplantation into an immunosuppressed B6 host. Arrow 
depicts induced BALT (n = 8). Scale bar: 100 μm. (C) PNAd staining 
(brown), (D) MT staining (blue), and (E) immunofluorescent staining 
of CCSP (red) and AcT (green) in BALB/c lung graft at least 30 days 
after transplantation into an immunosuppressed B6 host. Scale bars: 
100 μm. (F) Intravital 2-photon (2P) imaging depicting aggregates of 
Foxp3+ cells in BALB/c lung graft at least 30 days after transplantation 
into an immunosuppressed B6 Foxp3-IRES GFP recipient (Foxp3+ cells, 
green; quantum dot–labeled vessels, red) (n = 3). Scale bar: 30 μm.
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Figure 2. Depletion of graft-resident Foxp3+ T cells triggers AMR. (A) Schematic depicting experimental model. CSB, costimulation blockade. Plots and 
quantification of CD4+Foxp3+ cells from (B) primary (CD45.2) or (C) secondary recipient (CD45.1) in BALB/c lungs, transplanted into immunosuppressed 
WT B6 (CD45.2) (circles) or Foxp3-DTR B6 (CD45.2) (inverted triangles) mice and retransplanted into DT-treated B6 (CD45.1) hosts at least 30 days later. 
Plots are gated on live CD45.2+CD45.1–CD90.2+ and live CD45.2–CD45.1+CD90.2+ cells. (D) Plots and quantification of distribution of CD45.1 vs. CD45.2 on live 
CD90.2+CD4+CD8–Foxp3+ cells without and with depletion of graft-resident (CD45.2) Foxp3+ cells. Gross and histological appearance (H&E) of BALB/c lungs, 
transplanted into immunosuppressed WT (E and G) or Foxp3-DTR (F and H) B6 CD45.2+ mice and, at least 30 days later, retransplanted into DT-treated B6 
CD45.1+ hosts (n = 4 mice per group). (I) Airway epithelium (arrow) in human lung diagnosed with AMR (H&E) (n = 11). Staining of (J and K) MT (blue), (L and 
M) CCSP (red), AcT (green), and (N and O) C4d (brown) in BALB/c lungs, transplanted into immunosuppressed (J, L, and N) WT or (K, M, and O) Foxp3-DTR 
B6 CD45.2+ mice and, at least 30 days later, retransplanted into DT-treated B6 CD45.1+ hosts. Scale bars: 100 μm. Arrows in G, J, and L point to BALT. (P) 
Donor-specific IgM antibody titers 7 days after retransplantation of BALB/c lungs into DT-treated B6 CD45.1+ hosts at least 30 days after initial engraft-
ment into immunosuppressed B6 WT (red) or B6 Foxp3-DTR (blue) mice. (Q) Reactivity of serum IgM antibodies, following depletion of graft-resident 
Foxp3 cells, against donor (BALB/c), recipient (B6), and third-party (CBA) antigen (n = 4 mice per group). Data are expressed as mean ± SEM. Mann- 
Whitney U test was used to compare the means.
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of those observed in human pulmonary 
grafts that underwent AMR (Figure 2I). 
We also observed abnormal parenchy-
ma with interstitial fibrosis following 
depletion of graft-resident Foxp3+ T 
cells (Figure 2, J and K). Furthermore, 
in contrast to control retransplanted 
lungs, characterization of the airway 
epithelium by immunofluorescence of 
CCSP and AcT confirmed the absence 
of these normal epithelial markers in 
Foxp3+ T lymphocyte–depleted grafts, 
while the denuded intraluminal epithe-
lial remnant stained for CCSP (Figure 
2, L and M). We also observed deposi-
tion of complement fragments on endo-
thelial cells in arterioles, venules, and 
capillaries, and serum titers of donor- 
specific IgM antibodies were signifi-
cantly elevated following depletion of 
Foxp3+ T cells (Figure 2, N–P). Reactiv-
ity of the serum IgM antibodies against 
donor antigen was significantly higher 
than against recipient or third-party 
antigen (Figure 2Q).
At 30 days after retransplantation, 
control grafts displayed preserved 
lung architecture with induced BALT 
(Figure 3, A and B). In contrast, by 
gross examination, Foxp3+ T lympho-
cyte–depleted grafts appeared necrot-
ic at 30 days after retransplantation 
(Figure 3E). Interestingly, the airway 
epithelium 30 days after Foxp3+ T cell depletion showed some 
regeneration and hyperproliferation (Figure 3F). The parenchyma 
continued to appear abnormal, with increased fibrosis as well as 
substantial peribronchiolar and perivascular collagen deposition, 
while in comparison, control grafts showed minimal MT staining 
(Figure 3, C and G). Although the epithelium had regenerated and 
abundant AcT was detected, the expression of CCSP was aber-
rant, as it was absent throughout most of the airway, but present in 
confined areas, compared with the normal distribution seen in the 
control grafts (Figure 3, D and H). Interestingly, this is consistent 
with previous reports in humans showing an association between 
decreased CCSP expression and chronic rejection after lung 
transplantation (8). In addition to airway epithelial changes, we 
detected disorganized endothelium in the Foxp3+ T cell–depleted 
pulmonary grafts, where it appeared necrotic in some areas and 
the vessel lumen was filled with debris (Figure 3F). Serum levels of 
donor-specific IgG, but not IgM, were significantly higher 30 days 
after depletion of Foxp3+ T lymphocytes (Figure 3, I and J). Simi-
larly to our observations for IgM antibodies on day 7, reactivity of 
the serum IgG antibodies against donor antigen was significantly 
higher than against recipient or third-party antigen (Figure 3K).
Foxp3+ T cell depletion–triggered AMR is dependent on graft- 
infiltrating B cells. Having shown that transplanted lungs have his-
tological changes consistent with AMR after depletion of graft- 
contrast, Foxp3+ T cell depletion resulted in severe inflammation 
with histological evidence of hyaline membrane formation, alve-
olar edema, fibrinous deposits within the alveoli, and arteriolar 
fibrinoid necrosis, hallmarks of AMR in human lung grafts (Fig-
ure 2, E–H) (Supplemental Figure 8). Notably, these grafts showed 
no histological evidence of cellular rejection. Retransplantation 
of BALB/c lungs that were initially transplanted into B6 CD45.2 
Foxp3-DTR hosts and, at least 30 days later, retransplanted into 
PBS-treated secondary recipients yielded results comparable to 
those seen in retransplantation of BALB/c grafts that were initially 
transplanted into B6 CD45.2 WT hosts and then retransplanted 
into DT-treated secondary B6 CD45.1 mice (data not shown). Of 
note, most Foxp3+ T lymphocytes that had infiltrated the allograft 
from the primary recipient expressed CD25 and intracellular 
CTLA4 and displayed an effector memory phenotype (CD44hi 
CD62Llo). Moreover, the majority of Foxp3+ T cells expressed the 
proliferation marker Ki-67, and a small percentage of the Foxp3+ 
T lymphocytes expressed markers characteristic of T follicular 
regulatory (Tfr) cells (Supplemental Figure 9). When we evaluated 
the airway epithelium in the Foxp3+ T cell–depleted tissue, the epi-
thelium was completely destroyed, with epithelial remnants in the 
airway lumen (Figure 2H), in contrast with the control airway with 
hyperplastic epithelium (Figure 2G). The airway changes in the 
Foxp3+ T lymphocyte–depleted murine grafts were reminiscent 
Figure 3. Graft-resident Foxp3+ T cells maintain lung transplant tolerance. (A and E) Gross and (B and F) 
histological appearance (H&E), (C and G) MT staining (blue), and (D and H) immunofluorescent staining 
of CCSP (red) and AcT (green) in BALB/c lungs, initially transplanted into immunosuppressed (A–D) B6 
(CD45.2+) or (E–H) B6 Foxp3-DTR (CD45.2+) mice and retransplanted into DT-treated secondary B6 (CD45.1+) 
hosts at least 30 days after primary transplantation. Secondary hosts were examined 30 days after retrans-
plantation. Scale bars: 100 μm. Arrows in B and C point to BALT. Serum titers of donor-specific (I) IgM and 
(J) IgG antibodies 30 days after retransplantation of BALB/c lungs, initially transplanted into immunosup-
pressed B6 WT (red) or B6 Foxp3-DTR (blue) mice and, at least 30 days later, retransplanted into B6 45.1+ 
hosts. (K) Reactivity of serum IgG antibodies, following depletion of graft-resident Foxp3 cells, against donor 
(BALB/c), recipient (B6), and third-party (CBA) antigen. Data are expressed as mean ± SEM (n = 4 mice per 
group). Mann-Whitney U test was used to compare the means.
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planted tolerant BALB/c lungs 
into B6 muMT mice, which lack 
mature B cells, and depleted the 
graft-resident Foxp3+ T cells at 
the time of retransplantation. 
Foxp3+ T lymphocyte–depleted 
grafts were ventilated and showed 
no evidence of rejection 7 days 
after retransplantation into B6 
muMT mice (Figure 4, G and 
H). Similarly to tolerant lungs 
that were retransplanted into 
WT hosts without depletion of 
graft-resident Foxp3+ cells, these 
grafts showed evidence of BALT, 
with B and T lymphocytes as well 
as PNAd+ cells (Supplemental 
Figure 11, A and B). Preventing 
B lymphocyte graft infiltration 
after depletion of Foxp3+ T cells 
resulted in decreased collagen 
deposition (Figure 4I) compared 
with our observations in Foxp3+ T 
lymphocyte–depleted pulmonary 
grafts that were retransplanted 
into WT hosts (Figure 2K). The 
epithelial architecture remained 
intact and appeared hyperprolif-
erative compared with that shown 
with control grafts (Figure 4H). In 
addition, we observed an increase 
in the expression of CCSP and 
a decrease in the expression of 
AcT compared with Foxp3+ T 
cell–replete lung grafts, possibly 
indicating some epithelial repair 
(Figure 4J). Furthermore, we did 
not detect donor-specific IgM 
or IgG antibodies in the serum 
when secondary recipients lacked 
mature B cells (Figure 4K) (Sup-
plemental Figure 12).
In addition to their capacity to 
produce antibodies, B cells have 
been shown to contribute to graft 
rejection through antigen pre-
sentation (9). As B cells derived 
from the primary and secondary recipient were present in reject-
ing grafts, we wanted to determine whether antibody production 
by B cells that infiltrate the graft from the secondary recipient are 
critical for mediating graft rejection after Foxp3+ T lymphocyte 
depletion. For this purpose, we depleted Foxp3+ T cells from toler-
ant grafts following retransplantation into activation-induced cyt-
idine deaminase / secretory μ-chain double-knockout mice (B6 
AID/μS KO). These mice have B cells that cannot undergo affin-
ity maturation or secrete antibodies of any isotype (9). Similarly 
to our observations with B cell-deficient secondary recipients, 
resident Foxp3+ T lymphocytes, we next analyzed B lymphocytes 
in the lung allografts 7 days after retransplantation. The use of 
congenic CD45.1 secondary recipients allowed us to differenti-
ate between cells that had originated from the primary versus the 
secondary recipients. We observed a higher percentage of activat-
ed B cells from secondary, but not primary, recipient in Foxp3+ T 
cell–depleted grafts (Figure 4, A–F). A very small proportion of B 
cells in spleens of naive untransplanted mice expressed activa-
tion markers (Supplemental Figure 10). To evaluate the role of 
graft-infiltrating B cells in mediating rejection, we next retrans-
Figure 4. Graft-infiltrating B cells trigger AMR after depletion of graft-resident Foxp3+ T cells. Activated B cells 
from (A and B) primary recipient (CD45.2) or (C and D) secondary recipient (CD45.1) in BALB/c lungs, transplanted 
into immunosuppressed (A and C) B6 (CD45.2+) (no Foxp3 depletion) or (B and D) B6 Foxp3-DTR (CD45.2+) mice 
(Foxp3 depletion) and, at least 30 days later, retransplanted into DT-treated B6 (CD45.1+) hosts. Plots are gated 
on live CD45.2+CD45.1–B220+ (donor) and live CD45.2–CD45.1+B220+ cells (recipient). Quantification of activated 
(E) CD45.2 and (F) CD45.1 B cells in (circles) control and (inverted triangles) Foxp3+ T cell–depleted lungs 7 days 
after retransplantation. (G) Gross, (H) histological appearance (H&E), (I) MT staining (blue), and (J) CCSP (red) 
and AcT (green) staining in BALB/c lungs, transplanted into immunosuppressed B6 Foxp3-DTR mice and, at 
least 30 days later, retransplanted into DT-treated B6 muMt– hosts. (K) Donor-specific IgM titers 7 days after 
retransplantation of BALB/c lungs into DT-treated WT (blue) or muMt– (red) B6 hosts at least 30 days after 
engraftment into immunosuppressed B6 Foxp3-DTR mice. (L) Gross and (M) histological appearance (H&E) of 
BALB/c lungs, transplanted into immunosuppressed B6 Foxp3-DTR mice and, at least 30 days later, retrans-
planted into DT-treated B6 AID/μS knockout hosts. Scale bars: 100 μm. (N) Donor-specific IgM titers 7 days after 
retransplantation of BALB/c lungs into DT-treated WT (blue) or AID/μS knockout (red) B6 hosts at least 30 days 
after engraftment into immunosuppressed B6 Foxp3-DTR mice. Data are expressed as mean ± SEM (n = 4 mice 
per group). Mann-Whitney U test was used to compare the means.
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secondary recipients lacking the capacity to secrete antibodies 
did not reject grafts, the grafts retained BALT, and no significant 
elevations in serum DSA were detected (Figure 4, L–N) (Supple-
mental Figure 11, C and D). Thus, graft rejection after depletion of 
Foxp3+ T lymphocytes from tolerant pulmonary grafts depends on 
antibody production by graft-infiltrating B cells.
Foxp3+ T cell depletion–triggered AMR is dependent on graft- 
infiltrating T cells. Antibody production by B cells requires help, 
which can be provided by Tfh cells, a subset of T lymphocytes. 
Hallmarks of Tfh cells include expression of CXCR5 and PD-1 
as well as the transcription factor Bcl-6. Under both control and 
Foxp3+ T cell–depleted conditions, a fraction of CD4+ T cells that 
had originated from either the primary or secondary recipient 
expressed phenotypic markers characteristic of Tfh cells (Figure 
5, A–F). Only a small percentage of graft-infiltrating CD8+ T lym-
phocytes expressed granzyme B or perforin, irrespective of Foxp3+ 
T cell depletion (Supplemental Figure 13). To determine whether 
infiltration of T cells from the secondary recipient was necessary 
for triggering graft rejection following depletion of Foxp3+ T lym-
phocytes, we transplanted BALB/c lungs into B6 Foxp3-DTR mice 
that were treated with perioperative costimulatory blockade. At 
least 30 days later, these BALB/c lung grafts were retransplanted 
into B6 nude secondary recipients that were treated with DT at 
the time of retransplantation. Seven days after retransplantation, 
Figure 5. AMR after depletion of graft-resident Foxp3+ T 
cells is dependent on graft infiltration by T cells. Plots and 
histograms depicting markers characteristic of Tfh cells 
on CD4+ T cells derived from (A and C) primary (CD45.2) or 
(B and D) secondary (CD45.1) recipients in BALB/c lungs, 
initially transplanted into immunosuppressed (A and B) 
B6 (CD45.2+) or (C and D) B6 Foxp3-DTR (CD45.2+) mice 
and, at least 30 days later, retransplanted into DT-treated 
B6 (CD45.1+) hosts. Plots are gated on live CD45.2+CD45.1–
CD90.2+CD4+CD8–Foxp3– and CD45.2+CD45.1+CD90.2+ 
CD4+CD8–Foxp3– cells. Histograms are gated on CD4+ T cells 
that are PD-1hiCXCR5+ (bcl-6, red; isotype control, blue) 
(n = 4 each). Quantification of (E) CD45.2+ and (F) CD45.1+ 
CD4+ T cells that are PD-1hiCXCR5+ in (circles) control and 
(inverted triangles) Foxp3+ T cell–depleted lungs 7 days after 
retransplantation. (G) Gross and (H) histological appearance 
(H&E) and staining for (I) MT, (J) CCSP (red), and AcT (green) 
in BALB/c lungs, transplanted into immunosuppressed B6 
Foxp3-DTR mice and, at least 30 days later, retransplant-
ed into DT-treated B6 nude hosts. Scale bars: 100 μm. (K) 
Donor-specific IgM titers 7 days after retransplantation of 
BALB/c lungs into DT-treated WT (blue) or nude (red) B6 
hosts at least 30 days after initial engraftment into immu-
nosuppressed B6 Foxp3-DTR mice. Data are expressed as 
mean ± SEM (n = 4 mice per group). Mann-Whitney U test 
was used to compare the means.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
5 6 2 jci.org   Volume 129   Number 2   February 2019
Figure 6. Foxp3+ T lymphocyte depletion–triggered AMR is dependent on CXCL13-mediated chemokinesis. (A) Foxp3+ (green), B cells (blue), and CD4+  
T cells (red) in BALB/c lungs at least 30 days after transplantation into immunosuppressed B6 Foxp3-IRES GFP recipient (n = 3). Scale bar: 10 μm. CXCR5+ 
B cells from secondary host (recipient) in BALB/c lungs, initially transplanted into immunosuppressed (B) WT or (C) Foxp3-DTR B6 (CD45.2+) recipient and, 
at least 30 days later, retransplanted into DT-treated B6 CD45.1+ hosts. Plots are gated on live CD45.2–CD45.1+ cells. (D) CD45.1+CXCR5+ B cells in (circles) 
control and (inverted triangles) Foxp3+ T cell–depleted lungs 7 days after retransplantation (n = 4 each). CXCL13 (brown) in (E) control and (F) Foxp3+  
T cell–depleted grafts 7 days after retransplantation. Scale bars: 100 μm. CD4+ T cells (green) and B cells (blue) in BALB/c lungs, initially transplanted into 
immunosuppressed B6 Foxp3-DTR recipients and, at least 30 days later, retransplanted into B6 hosts, treated with (G) DT/control-Ig (arrows: CD4+ T–B 
cell interactions) or (H) DT/anti-CXCL13 (n = 2 each) (red, quantum dots). Scale bars: 20 μm. (I) Contact duration between CD4+ T and B cells, (J) CD4+ T, and 
(K) B cell mean square displacements and (L) CD4+ T and (M) B cell velocities within retransplanted Foxp3+ T cell–depleted BALB/c lungs with and without 
CXCL13 inhibition. (N) Gross, (O) histological appearance (H&E), staining for (P) MT (blue), (Q) CCSP (red), and AcT (green) in BALB/c lungs, transplanted 
into immunosuppressed B6 Foxp3-DTR mice and, at least 30 days later, retransplanted into DT- and anti-CXCL13–treated B6 hosts. Scale bars: 100 μm. 
(R) Donor-specific IgM titers after retransplantation of BALB/c lungs into DT-treated control (blue) or DT/anti-CXCL13 antibody–treated (red) B6 recipients 
after initial engraftment into immunosuppressed B6 Foxp3-DTR mice (n = 4 mice per group). Data are expressed as mean ± SEM. Mann-Whitney U test 
was used to compare the means.
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erative costimulatory blockade. At least 30 days after engraftment 
of the lungs, we injected recipient-matched CD4+ T cells and B cells 
that were labeled with fluorescent dyes. CD4+ T and B cells prefer-
entially migrated to areas in the graft where Foxp3+ T cell aggregates 
were present (Figure 6A and Supplemental Video 2). Both CD4+ T 
and B cells formed prolonged interactions with Foxp3+ T cells. As 
both CXCR5-expressing T and B cells of recipient origin (Figure 5D 
and Figure 6, B–D) were present in rejecting lung allografts following 
depletion of Foxp3+ T lymphocytes, we next wanted to investigate the 
role of the CXCR5 ligand CXCL13 in mediating interactions between 
T and B lymphocytes within lung grafts and promoting rejection. We 
first determined that CXCL13 was expressed within induced BALT 
in control tolerant retransplanted lungs and also in the interstitium of 
lungs that were acutely rejected after depletion of Foxp3+ T cells (Fig-
ure 6, E and F). We then evaluated how CXCR5-CXCL13 signaling 
regulates the dynamic behavior of T and B cells that infiltrate Foxp3+ 
T cell–depleted lung allografts. After injection of control antibodies, 
many T and B cells interacted with each other, often forming durable 
contacts (Figure 6G, Supplemental Video 3). In contrast, when we 
these grafts were ventilated and showed no evidence of rejection 
(Figure 5, G and H). Compared with Foxp3+ T cell–replete pul-
monary grafts, we observed a slight increase in collagen deposi-
tion, and airway epithelium was hyperproliferative (Figure 5, H 
and I). The expression patterns of CCSP and AcT appeared nor-
mal (Figure 5J) and were comparable to those in control Foxp3+ T 
cell–replete lungs (Figure 2L). Serum titers of donor-specific IgM 
antibodies were low and comparable to those under control con-
ditions, where tolerant BALB/c lungs were retransplanted into 
secondary B6 hosts without depletion of Foxp3+ T lymphocytes 
(Figure 5K and Figure 2P).
Foxp3+ T cell depletion–triggered AMR is dependent on CXCL13- 
mediated chemokinesis. Having shown that graft-infiltrating T and 
B cells are both critical in mediating production of DSA and graft 
rejection after depletion of Foxp3+ T cells, we set out to examine cel-
lular interactions within the transplanted lungs. We first evaluated 
whether graft-resident Foxp3+ T lymphocytes interact with B and T 
cells that infiltrate tolerant lung allografts. For this purpose, we trans-
planted BALB/c lungs into B6 Foxp3-GFP mice that received periop-
Figure 7. AMR of Foxp3+ T cell–depleted lung grafts can be prevented by blocking ICOS/ICOS ligand and CD40/CD40 ligand pathways. (A) Expression 
levels of ICOS, ICOS ligand (ICOSL), CD40, CD40 ligand (CD40L), and IL-21 in BALB/c lung grafts, which were initially transplanted into immunosuppressed 
B6 WT (CD45.2) (circles) or Foxp3-DTR B6 (CD45.2) (inverted triangles) mice and at least 30 days later retransplanted into DT-treated (days 0 and 1) B6 
CD45.1 hosts. Grafts were examined 7 days after retransplantation (n = 5 each). **P < 0.01. (B) Gross appearance, (C) histological appearance (H&E), (D) 
MT (blue) staining, (E) and immunofluorescent staining of CCSP (red) and AcT (green) after depletion of graft-resident Foxp3+ T cells and 7 days after 
retransplantation into anti-ICOS ligand and anti-CD40 ligand–treated secondary hosts. Scale bars: 100 μm. (F) Serum titers of donor-specific IgM 7 days 
after retransplantation of BALB/c lungs, initially transplanted into immunosuppressed B6 Foxp3-DTR mice and at least 30 days later retransplanted into 
DT-treated WT B6 hosts that were treated with anti-ICOS ligand and anti-CD40 ligand (red) or did not receive treatment (blue) (n = 4 mice per group). Data 
are expressed as mean ± SEM. Mann-Whitney U test was used to compare the means.
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after pulmonary transplantation is also regulated through cellular 
interactions in the graft. We demonstrate that hearts matching the 
strain of the original lung donor survive indefinitely without any 
evidence of graft rejection in the absence of additional immuno-
suppression. While third-party cardiac allografts are eventually 
rejected, they experience prolonged survival when transplanted 
into previous lung recipients. This observation is consistent with 
previous reports showing that, once activated, regulatory CD4+ 
T cells can suppress immune responses in an antigen-nonspe-
cific fashion (13). This phenomenon, which has been referred to 
as “bystander” regulation, has been demonstrated in vivo in the 
context of transplantation, where alloantigen-induced regulato-
ry CD4+ T cells are able to extend the survival of third-party skin 
allografts when reactivated by the original antigen (14). Of note, 
the existence of bystander regulation has raised concerns about 
the potential to compromise immunity to pathogens in transplant 
recipients, where tolerance is induced (15).
It has been the prevailing notion that the induction of tertiary 
lymphoid organs in allografts results in locally generated deleterious 
immune responses (16, 17). These structures have been observed in 
murine and human cardiac allografts that undergo either acute or 
chronic rejection (18, 19). Quilty lesions are endocardial lympho-
cytic infiltrates that have been observed in human heart grafts. To 
our knowledge, they lack hallmarks of organized tertiary lymphoid 
organs, such as PNAd-expressing high endothelial venules. While 
these lesions remain poorly understood, some studies have sug-
gested that they are associated with adverse events due to immune- 
mediated graft injury (20, 21). In rat aortic allografts, B cells residing 
within tertiary lymphoid organs have been suggested as contribut-
ing to chronic rejection through the local production of alloantibod-
ies (22). Similarly, induced BALT can propagate immune responses 
against viruses independently of secondary lymphoid organs (23). 
In contrast, we have previously reported that BALT is induced in 
long-term accepted lung allografts, which expresses peripheral 
node addressin — a hallmark of high endothelial venules — and is 
rich in Foxp3+ T cells (7). Interestingly, BALT-bearing tolerant lungs 
survive after transplantation into nonimmunosuppressed hosts, 
suggesting that immunoregulatory pathways that are established 
within the graft protect the lung from immunological destruction. 
Using Foxp3-DTR mice as intermediate hosts in a retransplant 
model allowed us to conclusively show that graft-resident Foxp3+ 
T lymphocytes, the vast majority of which form aggregates in the 
BALT, are critical to maintaining a tolerant state. The presence of 
regulatory T cells within transplanted tissues has been previously 
reported in murine skin grafts (24). Furthermore, there exist reports 
of Foxp3+ T cell–rich organized lymphoid aggregates in sponta-
neously accepted murine kidney allografts (25). Interestingly, glob-
al depletion of Foxp3+ T lymphocytes in recipient mice triggered 
cellular rejection of tolerant renal allografts, which was associated 
with graft infiltration by CD4+ and CD8+ T cells and an increased 
reactivity of recipient T cells against donor antigen. In contrast with 
our observations, depletion of Foxp3+ T cells in renal allograft recip-
ients did not result in changes in serum alloantibody levels, and 
grafts had no histological evidence of humoral rejection. Important 
differences exist between this study examining the role of Foxp3+ 
T lymphocytes in maintaining tolerance of kidney allografts and 
our investigation in lung allograft tolerance. First, it has not been 
injected CXCL13-neutralizing antibodies, we observed a decrease in 
the duration of interactions between T and B cells as well as signifi-
cant increases in their displacements and velocities (Figure 6, H–M, 
and Supplemental Video 4). Finally, neutralization of CXCL13 con-
current with depletion of Foxp3+ T cells prevented graft rejection and 
preserved the airway epithelium (Figure 6, N and O). Similarly to our 
observations after retransplantation of Foxp3+ T lymphocyte–deplet-
ed grafts into B cell–deficient hosts, there was some mild degree of 
peribronchiolar fibrosis, and CCSP expression appeared elevated, 
while AcT expression was decreased (Figure 6, P and Q). Finally, 
neutralization of CXCL13 did not result in significant elevation in 
serum titers of DSA following depletion of Foxp3+ T cells (Figure 6R).
Blockade of CD40 ligand and ICOS ligand prevents Foxp3+ T cell 
depletion–triggered AMR. Our results suggested that activation of 
B cells depended on their interaction with T cells within the graft. 
We then analyzed expression levels of genes that are known to be 
important in the activation of B cells by Tfh cells. Expression lev-
els of ICOS, ICOS ligand, CD40, and CD40 ligand, but not IL-21, 
were significantly elevated in Foxp3+ T cell–depleted compared 
with control lung allografts (Figure 7A). We then treated recipients 
of Foxp3+ T lymphocyte–depleted lung allografts with anti-ICOS 
ligand and anti-CD40 ligand. This regimen prevented graft rejec-
tion (Figure 7, B and C). We observed minimal peribronchial and 
perivascular collagen deposition (Figure 7D). The airway epitheli-
um in these grafts appeared normal, with slightly elevated expres-
sion of CCSP and normal expression of AcT (Figure 7E). Further-
more, blocking ICOS ligand and CD40 ligand pathways inhibited 
the generation of DSA (Figure 7F).
Discussion
Our study took advantage of a lung retransplant model to conclu-
sively demonstrate that graft-resident Foxp3+ T cells maintain a 
tolerant state. Surprisingly, AMR following Foxp3+ T lymphocyte 
depletion differs markedly from the cellular rejection pattern that 
we have previously reported in lungs following transplantation into 
nonimmunosuppressed hosts or when immunosuppression-medi-
ated graft acceptance is abrogated by ischemia reperfusion injury 
or respiratory bacterial infection (10, 11). Our experiments indi-
cate that depletion of Foxp3+ T cells allows B and T cell interac-
tions in lung allografts that result in the production of DSA and, 
ultimately, antibody-mediated destruction of the graft.
We have previously identified cell populations that are import-
ant for the induction of tolerance after lung transplantation. We 
showed that central memory CCR7+CD62LhiCD44hi CD8+ T cells 
induce acceptance of pulmonary allografts through IFN-γ–medi-
ated production of nitric oxide (5). CCR7-mediated synapses 
between CD8+ T cells and antigen-presenting cells within the 
lung allograft were important for the production of IFN-γ. More 
recently, we have demonstrated that graft-infiltrating eosinophils 
produce nitric oxide after stimulation with IFN-γ and that lungs 
are rejected when eosinophils are prevented from entering the 
graft (12). These findings demonstrate that immune events that 
regulate the induction of tolerance after pulmonary transplanta-
tion occur in the lung, setting this organ apart from other grafts in 
which downregulation of alloimmune responses depends on traf-
ficking of cells to draining lymph nodes (4). We have now extended 
these observations to show that maintenance of immune tolerance 
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imental evidence that loss of microvessels and tissue ischemia are 
associated with and can lead to fibrotic airway remodeling (38, 39).
Currently, there exists no standardized, universally accepted 
treatment regimen for patients who suffer from AMR after lung 
transplantation. Therapeutic approaches have been adopted 
from larger experiences with the treatment of antibody-mediat-
ed diseases and generally include B cell depletion strategies, i.v. 
immunoglobulin, plasmapheresis, and proteasome inhibitors. It 
is well established that T cells need to provide help to B cells in 
order to generate antigen-specific antibody responses. Consistent 
with this notion, the presence of recipient T cells was required 
for the production of DSA following depletion of graft-resident 
Foxp3+ T cells in our experiments. Antibody production following 
transplantation of allogeneic grafts has been shown to depend on 
interactions between CD4+ T cells with indirect alloreactivity and 
MHC II molecules on B cells, and our intravital imaging demon-
strates prolonged contact between recipient B and T cells in grafts 
that undergo AMR (40).
Tfh cells are specialized lymphocytes that express CXCR5 and 
high levels of PD-1 and ICOS, as well as the transcription factor 
Bcl-6, and can support antibody production by B cells through 
IL-21 as well as ICOS/ICOS ligand and CD40/CD40 ligand sig-
naling. In addition, B cell help can be provided by other T cell 
populations. For example, IL-21–producing Tfh-like cells that lack 
expression of CXCR5 or Bcl6 have been described in inflamed tis-
sues, where they can interact with B cells and promote their acti-
vation (41). While the frequencies of graft-infiltrating Tfh were not 
affected by depletion of graft-resident Foxp3+ cells, our findings 
that inhibition of CXCL13 altered the behavior of graft-infiltrat-
ing CD4+ T and B cells, as well as prevented the development of 
DSA and AMR, supports the notion that CXCR5-expressing T cells 
play an important role in triggering graft rejection in our model. 
Our findings extend recent observations in murine chronic graft- 
versus-host disease models in which development of fibrotic air-
way lesions could be prevented by similar interventions (42). Our 
imaging studies demonstrate that graft-resident Foxp3+ T cells 
interact with both graft-infiltrating CD4+ T and B cells and further 
suggest that DSA production and AMR following Foxp3+ T cell 
depletion depend on encounters between CD4+ T cells and B lym-
phocytes within the graft. Previous studies have shown that Foxp3+ 
regulatory T cells can inhibit B cell responses. For example, global 
depletion of Foxp3+ T lymphocytes in adult mice results in a CD4+ T 
cell–dependent activation of B cells in secondary lymphoid organs 
and the production of autoantibodies (43). A population of Foxp3+ 
T cells, referred to as Tfr cells, has been described that expresses 
markers characteristic of Tfh cells, including CXCR5, PD-1, and 
the transcription factor Bcl-6 (44). These Tfr cells can gain access 
to germinal centers, where they suppress B cell responses. Various 
mechanisms have been proposed as to how Foxp3+ T cells can sup-
press humoral responses. They may prevent the expansion of Tfh 
cells, possibly through inhibiting the activation of dendritic cells 
(43). Also, Foxp3+ T lymphocytes can directly inhibit Tfh cells or B 
lymphocytes, a process that has been shown to be dependent on 
their expression of CTLA4, which we have found to be expressed 
by the majority of graft-resident Foxp3+ T cells (45, 46). In addition, 
Foxp3+ T lymphocytes may prevent or disrupt interactions between 
Tfh cells and B lymphocytes. To this end, we have previously shown 
explored whether immune responses that regulate the fate of kid-
ney allografts occur in the graft itself or in draining secondary lym-
phoid organs. Unlike the BALT that is induced in tolerant lungs, 
Foxp3+ T cell–rich nodular aggregates in tolerant renal grafts lack 
expression of peripheral node addressin. Therefore, trafficking pat-
terns of immune cells may differ between tolerant lung and kidney 
grafts. Second, our retransplant model allowed us to target only 
Foxp3+ T cells that reside in the tolerant graft, while global deple-
tion of Foxp3+ T lymphocytes in Foxp3-DTR recipients could lead to 
more widespread inflammatory responses.
AMR has been increasingly recognized as a cause of adverse 
outcomes in recipients of solid organ grafts (26, 27). Clinically, hall-
marks of AMR of lungs include allograft dysfunction, presence of 
circulating DSA, capillary endothelial C4d deposition, and patho-
logic findings characteristic of acute lung injury, such as hyaline 
membrane formation (28). AMR cannot only lead to acute graft 
failure, but can also predispose patients to chronic lung allograft 
dysfunction (29). For example, a recent study identified de novo 
development of DSA as associated with an increased incidence of 
chronic allograft dysfunction after pulmonary transplantation (30). 
Similarly, obliterative bronchiolitis, a hallmark of chronic graft- 
versus-host disease following allogeneic bone marrow transplanta-
tion, was found to depend on production of alloantibodies by B cells 
in the donor inoculum (31). A recent study that employed transplan-
tation of human arterial grafts into immunodeficient mice proposed 
a mechanistic link between humoral alloimmune responses and 
chronic rejection (32). The authors demonstrated that activation 
of endothelial cells through binding of alloantibodies and deposi-
tion of complement promoted the recruitment and activation of 
alloreactive T cells, which resulted in the development of chronic 
vasculopathy. In our study, we have observed that circulating DSA 
are associated with the development of airway lesions that resemble 
those present in human lungs that undergo chronic rejection. While 
we demonstrate an important role for recipient T cells in the activa-
tion of B lymphocytes, their production of DSA, and the promotion 
of AMR, it is possible that — following activation of graft cells by 
alloantibodies — alloreactive T lymphocyte populations contribute 
to or potentiate pathologic changes that are characteristic of chron-
ic lung rejection. Mechanistically, several cell populations in lung 
allografts could be targets for antibody-mediated injury that results 
in airway remodeling. We found reduced expression of CCSP in 
lung grafts following depletion of Foxp3+ T lymphocytes; this was 
similar to previous findings in human lungs that developed obliter-
ative bronchiolitis (8). Club cells have been shown to play a role in 
tissue repair, and therefore, their loss may contribute to aberrant 
repair of injured airways in lung allografts (33). Alloantibody bind-
ing to ciliated airway epithelial cells in vitro can induce production 
of fibroblast growth factors, resulting in fibroblast proliferation (34). 
Endobronchial administration of antibodies directed against MHC 
class I or II molecules, which can target both ciliated and nonciliat-
ed airway epithelial cells, results in fibrotic airway changes that are 
reminiscent of those seen in human lung grafts that develop oblit-
erative bronchiolitis (35, 36). We have observed complement depo-
sition on the endothelium of small vessels after depletion of Foxp3+ 
T cells. Interestingly, microvascular injury triggered by antibody- 
mediated complement activation results in graft ischemia in ortho-
topic tracheal transplants (37). There exists both clinical and exper-
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(clone 1D3; BD Biosciences), CXCR5 (clone 2G8; BD Biosciences), 
PD-1 (clone J43; Thermofisher), Foxp3 (clone FJK-16s; Thermofisher), 
CTLA4 (clone UC10-4F10-11; BD Biosciences), perforin (clone eBio-
OMAK-D; Thermofisher), granzyme B (clone NGZB; Thermofisher), 
Ki-67 (clone SolA15; Thermofisher), Bcl-6 (clone K112-g1; BD Biosci-
ences), and isotype control antibodies (BD Biosciences, BioLegend, 
eBioscience, R&D Systems). Intracellular staining (Foxp3, CTLA4, 
Ki-67, Bcl-6, perforin, granzyme B) was performed as previously 
described (5). For determination of serum alloantibody titers, 200 μl 
aliquots of PBS with 0.5% BSA and 0.02% sodium azide (PBA) con-
taining 2 × 106 BALB/c, B6, or CBA/Ca thymocytes were mixed with 
200 μl of serially diluted serum for 1 hour at 4°C with frequent agita-
tion. After 3 washes with PBA, cells were stained for 30 minutes at 4°C 
with 100 μl of PBA containing 1 μl of polyclonal fluorochrome-conju-
gated goat anti-mouse IgM (μ chain specific) or anti-mouse IgG (Fcγ 
fragment specific) (Jackson ImmunoResearch). Cells were analyzed 
on a FACScan (BD Biosciences), and FlowJo software (FlowJo) was 
used to calculate the median fluorescence intensity.
Two-photon microscopy. Lung grafts were imaged by intravital 
2-photon microscopy at indicated time points for periods of up to 3 
hours, as previously described (52). Quantum dots (655 nm, 30 μl) (Life 
Technologies) were injected to label vessels. CD4+ T and B cells were 
isolated via positive selection with CD4 and B220 magnetic beads, 
respectively, from spleens of B6 mice (Miltenyi Biotec). We injected 
2 × 107 CD4+ T cells and 2 × 107 B cells, labeled with CFSE, CMTMR, 
or CellTrace Violet, as indicated for respective experiments, into 
lung recipients 24 hours prior to imaging (Life Technologies). Grafts 
were exposed and imaged with a custom 2-photon microscope using 
ImageWarp (A&B Software). Sequential z-sections (2.5 μm each) were 
acquired, yielding an imaging volume of 220 × 247.5 × 50 μm3. Anal-
yses were performed with Imaris (Bitplane). For each mouse, up to 5 
lung areas at least 80 μm deep were analyzed (5).
Quantitative PCR. Homogenized lung graft tissue was lysed with 
TRIzol (Thermo Fisher Scientific), as previously described (53). Total 
RNA was isolated using QIAGEN RNeasy Mini Kit (QIAGEN), and quan-
titative PCR was performed as previously described. Primer sequenc-
es were as follows: ICOS, 5′-ATGAAGCCGTACTTCTGCCG-3′ and 
5′-CGCATTTTTAACTGCTGGACAG-3′; ICOSL, 5′-TAAAGTGTC-
CCTGTTTTGTGTCC-3′ and 5′-ATTGCACCGACTTCAGTCTCT-3′; 
CD40L, 5′-CCTTGCTGAACTGTGAGGAGA-3′ and 5′-CTTCGCTTA-
CAACGTGTGCT-3′; CD40, 5′-TGTCATCTGTGAAAAGGTGGTC-3′ 
and 5′-ACTGGAGCAGCGGTGTTATG-3′; and IL-21, 5′-TGCATCAGT-
GACGGTAAACCA-3′ and 5′-CACAGTTTGGAGTGTTGAGGAT-3′.
Histology. Transplanted mouse lungs or hearts as well as human 
transbronchial biopsies were fixed in formaldehyde, sectioned, and 
stained with H&E (lungs and hearts) or MT (lungs). A surgical pathol-
ogist blinded to the experimental conditions assessed grafts stained 
with H&E for rejection.
Immunostaining. For immunohistochemistry, formalin-fixed, 5 μm 
sections of paraffin-embedded specimens were deparaffinized and 
rehydrated. Following antigen retrieval in citrate buffer (pH 6.0, Dako), 
endogenous peroxide activity was quenched with 3% H2O2. The slides 
were washed in PBS with 1.5% BSA and 0.1% Tween-20 (PBT). Nonspe-
cific immunobinding sites were blocked with 10% normal rabbit serum 
(Vector S-5000) or serum-free protein block (Dako) for PNAd or Foxp3/
CXCL13, respectively. For Foxp3 and CXCL13 staining, the specimens 
were sequentially incubated in avidin D and biotin blocking solution 
that lymphocytes infiltrating tolerant lung allografts preferentially 
migrate to the induced BALT (7). Thus, our findings suggest that 
graft-infiltrating alloreactive B and T lymphocytes are inhibited 
following their encounter with Foxp3+ T cells in the BALT, thereby 
preventing them from mounting alloimmune responses.
In conclusion, our observations advance our understanding of 
mechanisms that trigger AMR and have important implications for 
the clinical management of lung transplant patients. Our findings 
that BALT-resident Foxp3+ T cells inhibit the generation of humor-
al responses substantiate the notion that local immune responses 
regulate the fate of transplanted lungs. Thus, strategies to induce 
and maintain Foxp3+ T cell–rich BALT in pulmonary allografts 
may improve survival after lung transplantation. We suggest that 
the rapid tempo of AMR in our model is related to the pharmaco-
logically induced rapid and complete depletion of graft-resident 
Foxp3+ cells. Respiratory viral infections, an established risk factor 
for the generation of de novo DSA, have been shown to compro-
mise the suppressive functions of pulmonary regulatory T cells 
(47). This raises the possibility that such infections can disrupt 
local immunoregulatory pathways in lung transplant patients and 
trigger AMR, albeit at a slower rate compared with the tempo 
observed in our model (47, 48). Given that AMR is largely refrac-
tory to current immunosuppression, our observations provide a 
rationale for targeting costimulatory or chemotactic pathways that 
promote the activation of B lymphocytes by Tfh cells.
Methods
Mice and reagents. B6 (CD45.2), B6.SJL-PtprcaPepcb/BoyJ (CD45.1), 
BALB/c, CBA/Ca, B6 Foxp3-DTR, B6 Foxp3 IRES-GFP, B6 nude, and 
B6.129S2-Ighmtm1Cgn/J (muMt–) mice were purchased from The Jackson 
Laboratory. B6 AID/μS KO mice were provided by G. Chalassani (Uni-
versity of Pittsburgh, Pittsburgh, Pennsylvania, USA) after obtaining 
permission from F. Lund (University of Alabama, Birmingham, Ala-
bama, USA) (9). Primary lung transplant recipients were treated with 
costimulatory blockade consisting of anti-CD40 ligand (250 μg i.p.) 
and CTLA4-Ig (200 μg i.p.) on days 0 and 2, respectively (Bio X Cell). 
To deplete graft-resident Foxp3+ cells, DT (List Biologic Laboratories 
Inc.) (1 μg i.p.) was administered at the time of retransplantation (days 
0, 1) to secondary recipients receiving grafts that had initially been 
transplanted into Foxp3-DTR hosts. Some retransplant recipients were 
treated with anti-ICOS ligand (200 μg i.p., days 0, 2, 4, 6) and anti-
CD40 ligand antibodies (250 μg i.p., days 0, 2, 4, 6) or anti-murine 
CXCL13 antibodies (200 μg i.p., days 0, 2, 4, 6, after retransplantation 
for survival studies; and 200 μg i.p., days 0, 1, 2, for intravital imaging 
studies) (R&D Systems). Six- to ten-week-old mice were used for the 
studies. Sex-matched mice were used for the transplant procedures.
Surgical procedures. Orthotopic murine left lung transplants and 
retransplants as well as heterotopic heart transplants into the recipi-
ent’s right neck were performed as previously described (49–51).
Flow cytometry. Lung tissue was digested, and single-cell suspen-
sions were prepared as previously described (5, 49). Cells were then 
stained using CD45.2 (clone 104; Thermofisher), CD45.1 (clone A20; 
BD Biosciences), CD90.2 (clone 53-2.1; Thermofisher), CD4 (clone 
RM4-5; Biolegend), CD8α (clone 53.6.7; Thermofisher), CD62L 
(clone MEL-14; Biolegend), CD44 (clone IM7; eBiosciences), CD25 
(clone PC61; Biolegend), Fas (clone Jo2; BD Biosciences), GL7 (clone 
GL7; BD Biosciences), B220 (clone RA3-6B2; eBiosciences), CD19 
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perature. Slides were extensively washed in PBS and coverslipped with 
DAPI (MilliporeSigma) in Fluoromount-G mounting media (Southern 
Biotech). Images were obtained using a Zeiss Observer.Z1 inverted 
fluorescent microscope (Carl Zeiss Inc.) equipped with a digital cam-
era and processed using AxioVision release 4.6.3 (Carl Zeiss) software.
Statistics. Data were analyzed with the Mann-Whitney U test, 
which was performed using GraphPad Prism, version 7.0 (GraphPad 
Software). Data were graphed as mean ± SEM. Cardiac allograft sur-
vival was compared between groups with Kaplan-Meier analysis. Data 
were considered statistically significant at P < 0.05.
Study approval. Animal experiments were approved by the Institu-
tional Animal Studies Committee at Washington University. Animals 
received humane care in compliance with the Guide for the Care and 
Use of Laboratory Animals (National Academies Press, 2011) and with 
the Principles of Laboratory Animal Care formulated by the National 
Society for Medical Research. Human protocols were approved by the 
Institutional Review Board at Washington University School of Medi-
cine (no. 201811073). Patients provided informed consent.
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